Home Categories API Lopinavir
A4721331

Lopinavir , 95% , 192725-17-0

Synonym(s):
(αS)-N-[(1S,3S,4S)-4-[[(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-;Lopinavir

CAS NO.:192725-17-0

Empirical Formula: C37H48N4O5

Molecular Weight: 628.81

MDL number: MFCD04973616

EINECS: 200-001-8

Pack Size Price Stock Quantity
10mg RMB31.20 In Stock
50mg RMB95.20 In Stock
250mg RMB279.20 In Stock
1g RMB799.20 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 255.2-260.6 °F (124—127°C)
Boiling point: 924.1±65.0 °C(Predicted)
Density  1.163±0.06 g/cm3(Predicted)
storage temp.  2-8°C
solubility  DMSO: soluble20mg/mL, clear
pka 13.89±0.46(Predicted)
form  powder
color  white to beige
optical activity [α]/D -20 to -27°, c = 0.4 in methanol
Stability: Hygroscopic
CAS DataBase Reference 192725-17-0(CAS DataBase Reference)

Description and Uses

Lopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action. Ritonavir inhibits the P450 isoenzyme CYP3A4 and the human liver microsomal metabolism of lopinavir, so strongly amplifying plasma levels of this latter component. In AIDS patients, the plasma HIV RNA level was considerably reduced and the CD4+ T-cell counts increased after administration of lopinavir combined with relatively small doses of ritonavir. Kaletra is intended to be used jointly with other antiretroviral agents.

A selective HIV protease inhibitor. An analogue of Ritonavir. Antiviral.

Safety

Symbol(GHS) 
GHS07,GHS08
Signal word  Warning
Hazard statements  H315-H373-H319-H335
Precautionary statements  P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P-P260-P314-P501
RIDADR  3077
HS Code  29335990
Hazardous Substances Data 192725-17-0(Hazardous Substances Data)

RELATED PRODUCTS